EuropaBio’s launch meeting for Biotech Week will share how science finds its way to an end use, whether it is a new medicine, or a product developed using new scientific processes.
The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof, patient-oriented and leading life science and biotechnology sector in the EU.
With the Green Deal, the EU has set an ambitious strategy towards climate neutrality, transitioning to a circular economy and a more sustainable food system
The 2022 European Biotech Week from EuropaBio opens with a look at how biotechnology is at the centre of Europe’s transformation to a healthy, sustainable and […]
Industrial Biotechnology-derived products offer significant potential for contributing to overcoming many EU socio-economic and environmental challenges. It is not a new sector. On the contrary, for […]
Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients, both in terms of innovative treatments, but also via use of innovative prevention, […]
The world is at a key point of industrial and societal transition, driven by advancing technology and the need for competitive, resilient and sustainable economies.
Biotechnology is at the heart of this transition across all sectors and it is playing a significant role in shaping Europe’s future.
